– Reuters
SVB Leerink Maintains Outperform on Amylyx Pharma, Raises Price Target to $50
SVB Leerink analyst Marc Goodman maintains Amylyx Pharma (NASDAQ:AMLX) with a Outperform and raises the price target from $31 to $50.
Related Posts
JPMorgan, Morgan Stanley And 3 Stocks To Watch Heading Into Friday
With US stock futures trading slightly higher this morning on Friday, some of the stocks that may grab investor focus today are as follows:
Shiba Inu Burn Rate Spikes 182% After Card-Shaped Cold Wallets Announced
Tangem, a Swiss-based crypto wallet company, is developing unique cold wallets specifically designed for the Shiba Inu (CRYPTO: SHIB) meme coin.
Gene Therapy Player REGENXBIO’s RGX-121 Marks Success In Trial, Yet Faces Challenges In A Crowded Market: Analyst
Insights from Wedbush analysts about the clinical effectiveness of REGENXBIO's RGX-202, market potential, and challenges posed by competitors like Sarepta Therapeutics and Pfizer.